MedTrace Logo

Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors

NCT04975958 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2025-06-22

No results posted yet for this study

Summary

This is an open-label, multicenter, Phase 1a study to evaluate the safety, tolerability, PK and preliminary efficacy of AN2025 and AN0025 in double or triple combination treatments with Atezolizumab in patients with locally advanced/metastatic tumors.

Conditions

  • Locally Advanced Solid Tumor

Interventions

DRUG

AN2025

oral administration

DRUG

AN0025

oral administration

DRUG

Atezolizumab 1200 mg in 20 ML Injection

infusion

Sponsors & Collaborators

  • Adlai Nortye Biopharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Robert Atkinson, PhD, MSCR · Adlai Nortye US Inc

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-07
Primary Completion
2025-01-24
Completion
2025-01-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04975958 on ClinicalTrials.gov